-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下: 2026年第一季度业绩略超预期,销售额达159亿美元(同比增长9%),非GAAP每股收益为1.91美元(同比增长19%),分别高于市场普遍预期的157亿美元和1.81美元。按固定汇率计算,销售额增长6%,较前两个季度的9%和7%有所放缓,但管理层维持了2026年按固定汇率计算的收入增长“超过5%”和自由现金流约为157亿美元的预期。软件业务按固定汇率计算的增长从第四季度的11%和第三季度的9%放缓至8%,这可能对空头构成潜在风险信号,尽管红帽业务的增长从第四季度的8%反弹至10%。因此,我们预计近期持续约20%的订单增长将支撑今年两位数左右的销售额增长。基础设施业务保持强劲增长,按固定汇率计算增长12%,IBM Z系列产品销售额同比增长51%,但未来增长将面临更大的基数压力。我们认为IBM营业利润率同比增长110个基点令人印象深刻,而咨询业务的韧性(销售额增长1%,签约量增长10%)至少在目前应该能够缓解人们对Anthropic相关COBOL竞争的担忧。
Related Articles
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.